BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22523320)

  • 21. Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins.
    Metz S; Wiesinger M; Vogt M; Lauks H; Schmalzing G; Heinrich PC; Müller-Newen G
    J Biol Chem; 2007 Jan; 282(2):1238-48. PubMed ID: 17085445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein.
    Chevalier S; Fourcin M; Robledo O; Wijdenes J; Pouplard-Barthelaix A; Gascan H
    J Biol Chem; 1996 Jun; 271(25):14764-72. PubMed ID: 8662918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130.
    Waetzig GH; Chalaris A; Rosenstiel P; Suthaus J; Holland C; Karl N; Vallés Uriarte L; Till A; Scheller J; Grötzinger J; Schreiber S; Rose-John S; Seegert D
    J Biol Chem; 2010 Jan; 285(3):1781-9. PubMed ID: 19915009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies.
    Rinis N; Küster A; Schmitz-Van de Leur H; Mohr A; Müller-Newen G
    Cell Commun Signal; 2014 Mar; 12():14. PubMed ID: 24612692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.
    Adam N; Rabe B; Suthaus J; Grötzinger J; Rose-John S; Scheller J
    J Virol; 2009 May; 83(10):5117-26. PubMed ID: 19264784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer.
    Garbers C; Spudy B; Aparicio-Siegmund S; Waetzig GH; Sommer J; Hölscher C; Rose-John S; Grötzinger J; Lorenzen I; Scheller J
    J Biol Chem; 2013 Feb; 288(6):4346-54. PubMed ID: 23209286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver.
    Graf D; Kohlmann C; Haselow K; Gehrmann T; Bode JG; Häussinger D
    Hepatology; 2006 Nov; 44(5):1206-17. PubMed ID: 17058237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb.
    Autissier P; De Vos J; Liautard J; Tupitsyn N; Jacquet C; Chavdia N; Klein B; Brochier J; Gaillard JP
    Int Immunol; 1998 Dec; 10(12):1881-9. PubMed ID: 9885909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II.
    Duplomb L; Chaigne-Delalande B; Vusio P; Raher S; Jacques Y; Godard A; Blanchard F
    Endocrinology; 2003 Dec; 144(12):5381-9. PubMed ID: 12959977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. gp130 activation is regulated by D2-D3 interdomain connectivity.
    Schütt A; Zacharias M; Schneider N; Horn S; Grötzinger J; Rose-John S; Schmidt-Arras D
    Biochem J; 2013 Mar; 450(3):487-96. PubMed ID: 23294003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gp130 cytokines exert differential patterns of crosstalk in adipocytes both in vitro and in vivo.
    White UA; Stewart WC; Stephens JM
    Obesity (Silver Spring); 2011 May; 19(5):903-10. PubMed ID: 21164505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the interleukin-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies.
    Müller-Newen G; Küster A; Wijdenes J; Schaper F; Heinrich PC
    J Biol Chem; 2000 Feb; 275(7):4579-86. PubMed ID: 10671483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine signalling via gp130 in gastric cancer.
    Howlett M; Menheniott TR; Judd LM; Giraud AS
    Biochim Biophys Acta; 2009 Nov; 1793(11):1623-33. PubMed ID: 19665497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6).IL-6 receptor.gp130 complex.
    Horsten U; Müller-Newen G; Gerhartz C; Wollmer A; Wijdenes J; Heinrich PC; Grötzinger J
    J Biol Chem; 1997 Sep; 272(38):23748-57. PubMed ID: 9295319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor.
    Ancey C; Küster A; Haan S; Herrmann A; Heinrich PC; Müller-Newen G
    J Biol Chem; 2003 May; 278(19):16968-72. PubMed ID: 12646580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
    Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
    PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
    Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
    J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M.
    Gu ZJ; Wijdenes J; Zhang XG; Hallet MM; Clement C; Klein B
    J Immunol Methods; 1996 Mar; 190(1):21-7. PubMed ID: 8601708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling.
    Lin M; Rose-John S; Grötzinger J; Conrad U; Scheller J
    Biochem J; 2006 Sep; 398(3):577-83. PubMed ID: 16716147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.